Uniphar

On track for another year of double-digit growth

  • Sectors : Pharma and healthcare
  • Companies : Uniphar

Ratings and price correct at time of issue.

  • Uniphar

    Closing Price: 380c

  • RATING 27/08/19

  • PREVIOUS RATING N/A

DAVY VIEW

Uniphar has delivered an ‘in-line’ trading update for H1 2022 and remains on track to deliver strong, double-digit EPS growth this year (we forecast +18%). This follows 29% last year and 24% the year prior, and reinforces the resilience of Uniphar’s business model against various challenging backdrops (pandemic, macro, inflation). Underpinning future growth, it also maintains an active M&A pipeline across all three divisions. The stock trades on 2023 17.7x P/E, which we find attractive given the group’s strong medium-term growth prospects.

Download full report with analyst certification and important disclosures

Jul 26 2022, 07:15 IST/BST

Download